Search
Neratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalApproval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. … Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer.
Ferric pyrophosphate
go.drugbank.com/drugs/DB09147ApprovedInvestigational[A31979] It presents an increasing interest as this insoluble form can be milder in the gastrointestinal tract and present higher bioavailability.[L1433]
Cabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalfor the treatment of hepatocellular carcinoma in previously treated patients. … It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.
Amisulpride
go.drugbank.com/drugs/DB06288ApprovedInvestigational[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders … In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of
Trifluridine
go.drugbank.com/drugs/DB00432ApprovedInvestigationalThe combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal
Cilomilast
go.drugbank.com/drugs/DB03849InvestigationalCilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). … Following four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile.
Binimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigational[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients … with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Fluspirilene
go.drugbank.com/drugs/DB04842ApprovedWithdrawnA long-acting injectable antipsychotic agent used for chronic schizophrenia.
Starch, corn
go.drugbank.com/drugs/DB11599ApprovedInvestigationalNutraceuticalStarch is the chief storage form of energy reserve (carbohydrates) in plants. … Starch is any of a group of polysaccharides of the general formula (C6-H10-O5)n, composed of a long-chain polymer of glucose in the form of amylose and amylopectin.
Categories: Compounds used in a research, industrial, or household settingRepaglinide
go.drugbank.com/drugs/DB00912ApprovedInvestigationalRepaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Meglitnides may have a neutral effect on weight or cause a slight increase in weight.